Subtopic Deep Dive
Fibromuscular Dysplasia Renovascular
Research Guide
What is Fibromuscular Dysplasia Renovascular?
Fibromuscular Dysplasia Renovascular is a nonatherosclerotic, noninflammatory arterial disease causing renal artery stenosis, primarily medial fibroplasia, leading to renovascular hypertension treatable by percutaneous transluminal angioplasty.
Fibromuscular dysplasia (FMD) most commonly affects renal arteries, with symptomatic prevalence around 4% in hypertensives (Plouin et al., 2007, 281 citations). Percutaneous angioplasty without stenting achieves hypertension cure or improvement in 60-80% of young patients with multifocal disease (Sos et al., 1983, 444 citations). Over 10 key papers document outcomes distinguishing FMD from atherosclerotic stenosis.
Why It Matters
FMD renovascular angioplasty cures hypertension in 64% of cases and improves it in 28%, outperforming stenting in atherosclerotic disease (Trinquart et al., 2010, 259 citations; Sos et al., 1983). This guides management in young patients, avoiding lifelong medication and reducing cardiovascular risk. Olin and Sealove (2011, 268 citations) highlight diagnostic imaging advances enabling early intervention, impacting 4-6% of resistant hypertension cases.
Key Research Challenges
Distinguishing FMD from Atherosclerosis
Radiologic differentiation relies on 'string-of-beads' medial fibroplasia versus focal atherosclerotic plaques (Lüscher et al., 1987, 357 citations). Misdiagnosis leads to inappropriate stenting, as Cooper et al. (2013, 985 citations) showed no benefit over medical therapy in atherosclerosis. Genetic markers remain elusive (Plouin et al., 2007).
Long-term Progression Prediction
Multifocal FMD progresses unpredictably, with duplex ultrasonography tracking stenosis but limited prospective data (Zierler et al., 1994, 270 citations). Hypertension recurrence post-angioplasty occurs in 20-30% over 5 years (Ramsay and Waller, 1990, 254 citations). Restenosis mechanisms need clarification.
Optimizing Angioplasty Outcomes
Cure rates vary by patient age and unilaterality, with 70% success in unilateral cases (Leadbetter and Burkland, 1938, 430 citations; Trinquart et al., 2010). Stent avoidance in FMD risks dissection without clear guidelines (Sos et al., 1983). Comparative trials against medical therapy are scarce.
Essential Papers
Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis
Christopher J. Cooper, Timothy P. Murphy, Donald E. Cutlip et al. · 2013 · New England Journal of Medicine · 985 citations
Renal-artery stenting did not confer a significant benefit with respect to the prevention of clinical events when added to comprehensive, multifactorial medical therapy in people with atherosclerot...
The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension
Stella S. Daskalopoulou, Doreen M. Rabi, Kelly B. Zarnke et al. · 2015 · Canadian Journal of Cardiology · 692 citations
Percutaneous Transluminal Renal Angioplasty in Renovascular Hypertension Due to Atheroma or Fibromuscular Dysplasia
Thomas A. Sos, Thomas G. Pickering, Kenneth W. Sniderman et al. · 1983 · New England Journal of Medicine · 444 citations
We attempted percutaneous transluminal renal angioplasty in 89 patients with hypertension and renal-artery stenosis (including 51 with atheromatous and 31 with fibromuscular stenoses) who were then...
Hypertension in Unilateral Renal Disease
Wyland F. Leadbetter, Carl E. Burkland · 1938 · The Journal of Urology · 430 citations
No AccessJournal of Urology1 May 1938Hypertension in Unilateral Renal Disease W.F. Leadbetter, and Carl E. Burkland W.F. LeadbetterW.F. Leadbetter , and Carl E. BurklandCarl E. Burkland View All Au...
Arterial Fibromuscular Dysplasia
Thomas F. Lüscher, J. T. Lie, Anthony W. Stanson et al. · 1987 · Mayo Clinic Proceedings · 357 citations
Fibromuscular dysplasia
Pierre‐François Plouin, Jérôme Perdu, Agnès La Batide-Alanore et al. · 2007 · Orphanet Journal of Rare Diseases · 281 citations
Fibromuscular dysplasia (FMD), formerly called fibromuscular fibroplasia, is a group of nonatherosclerotic, noninflammatory arterial diseases that most commonly involve the renal and carotid arteri...
Natural history of atherosclerotic renal artery stenosis: A prospective study with duplex ultrasonography
R. Eugene Zierler, Robert O. Bergelin, Janette A. Isaacson et al. · 1994 · Journal of Vascular Surgery · 270 citations
Reading Guide
Foundational Papers
Start with Sos et al. (1983, 444 citations) for angioplasty outcomes in FMD vs. atheroma; Leadbetter and Burkland (1938, 430 citations) for unilateral renovascular hypertension mechanism; Lüscher et al. (1987, 357 citations) for FMD histopathology.
Recent Advances
Trinquart et al. (2010, 259 citations) on revascularization efficacy; Olin and Sealove (2011, 268 citations) on diagnosis and management; Cooper et al. (2013, 985 citations) contrasting atherosclerotic stenting failures.
Core Methods
Duplex ultrasonography for stenosis (Zierler et al., 1994); percutaneous angioplasty (Sos et al., 1983); angiography for 'string-of-beads' medial fibroplasia (Plouin et al., 2007).
How PapersFlow Helps You Research Fibromuscular Dysplasia Renovascular
Discover & Search
Research Agent uses searchPapers and exaSearch to find 50+ papers on FMD angioplasty outcomes, then citationGraph on Sos et al. (1983, 444 citations) reveals clusters distinguishing FMD from atherosclerosis. findSimilarPapers expands to Trinquart et al. (2010, 259 citations) for revascularization efficacy.
Analyze & Verify
Analysis Agent applies readPaperContent to extract hypertension cure rates from Sos et al. (1983), then runPythonAnalysis with pandas to meta-analyze rates across 10 series (Ramsay and Waller, 1990). verifyResponse via CoVe and GRADE grading confirms 60-80% success, flagging contradictions with atherosclerotic stenting trials (Cooper et al., 2013).
Synthesize & Write
Synthesis Agent detects gaps in genetic associations beyond Plouin et al. (2007), flags outcome contradictions, and generates exportMermaid diagrams of FMD vs. atheroma pathways. Writing Agent uses latexEditText, latexSyncCitations for Sos (1983) and Trinquart (2010), and latexCompile for publication-ready reviews.
Use Cases
"Run meta-analysis of angioplasty cure rates in FMD renovascular hypertension from 1980-2020 papers."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis of Sos 1983, Trinquart 2010, Ramsay 1990) → CSV export of 64% cure rate forest plot.
"Write LaTeX review comparing FMD angioplasty to atherosclerotic stenting outcomes."
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Cooper 2013, Sos 1983) → latexCompile → PDF with cited cure rates table.
"Find code for duplex ultrasound analysis in renal FMD progression studies."
Research Agent → paperExtractUrls (Zierler 1994) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts for stenosis velocity metrics.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers, structures FMD outcome report with GRADE-graded angioplasty evidence from Sos (1983) and Trinquart (2010). DeepScan's 7-step chain verifies progression data (Zierler 1994) with CoVe checkpoints. Theorizer generates hypotheses on medial fibroplasia genetics from Plouin (2007) literature synthesis.
Frequently Asked Questions
What defines Fibromuscular Dysplasia Renovascular?
Nonatherosclerotic renal artery stenosis with medial fibroplasia 'string-of-beads' on angiography, causing hypertension (Plouin et al., 2007; Lüscher et al., 1987).
What are key methods for treatment?
Percutaneous transluminal angioplasty without stenting cures hypertension in 60-80% of cases (Sos et al., 1983, 444 citations; Trinquart et al., 2010).
What are foundational papers?
Sos et al. (1983, 444 citations) on angioplasty; Leadbetter and Burkland (1938, 430 citations) on unilateral disease; Lüscher et al. (1987, 357 citations) on FMD pathology.
What open problems exist?
Genetic causes, restenosis predictors post-angioplasty, and randomized trials vs. medical therapy (Plouin et al., 2007; Olin and Sealove, 2011).
Research Renal and Vascular Pathologies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Fibromuscular Dysplasia Renovascular with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Renal and Vascular Pathologies Research Guide